Objective: Use propensity score methods to explore the effect of parenterally administered Shenqi Fuzheng on clinical outcome of patients with tumor.
Method: HIS data from 20 hospitals was analyzed. Patients suffering from malignant tumor, ranging from 18 to 80 years, Were divided into the treatment group and control group. The treatment group was given parenterally administered Shenqi Fuzheng, the control group received other parenterally administered anti-cancer medicines. Various levels of controls for confounding factors were applied, including chi-square test, Fisher exact test, stratified analysis, logistic regression, and logistic regression based on adjusted propensity score, to assess parenterally administered Shenqi Fuzheng's clinical effects.
Result: Stratified analysis showed that among elderly patients whose condition was classified as either 'urgent' or 'dangerous'. Comparing these two sub-groups it was found that the test P < 0.05. The treatment group had a significantly lower mortality rate than the control group. After adjusting for 72 confounding factors, the statistical results also show that the mortality rate overall in the treatment group was significantly lower than in the control group.
Conclusion: Analysis of HIS data showed that parenterally administered Shenqi Fuzheng can reduce mortality due to malignant cancer when compared to other available treatments.